Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib Extension Study in Active Moderate to Severe Thyroid Eye Disease
2022-502812-35-00Phase 2Completed
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of linsitinib in Graves Orbitopathy (GO) (3 arms), sponsored by Sling Therapeutics, Inc. Primary endpoint: Proptosis responder rate at Extension study Week 24. Started Jul 2023; status: completed.
02
Drugs
linsitinib
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2022-502812-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502812-35-00.